Newer medicine options, including the sodium-glucose cotransport 2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, have been shown to protect the heart and reduce the risk of many specific heart-related outcomes for people with type 2 diabetes
Clinical Evidence in Asian Indian Patients The Indian thin fat phenotype is more prone to the development of T2DM and is associated with several unique features, such as early age of T2DM onset, early decline in beta cell mass, higher insulin resistance, higher carbohydrate intake and physical inactivity leading to central obesity, unique dyslipidemia pattern, increased CV disease risk, higher association with nonalcoholic fatty liver disease, among others [29,30,31]
The team highlights a patent-pending peptide and yeast delivery platform, cGMP manufacturing, and third-party testing for identity, purity, and potency
Eat when you are hungry and stop when you are full
These risks primarily involved the digestive system and included nausea and vomiting, stomach pain, heartburn and gastroparesis, or stomach paralysis